Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

Advances in androgen receptor targeted therapy for prostate cancer.

Ahmed A, Ali S, Sarkar FH.

J Cell Physiol. 2014 Mar;229(3):271-6. doi: 10.1002/jcp.24456. Review.

2.

Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer.

Nguyen MM, Wang Z.

Minerva Urol Nefrol. 2008 Mar;60(1):15-29. Review.

PMID:
18427432
3.

Lessons from in-vivo models of castration-resistant prostate cancer.

Lin D, Gout PW, Wang Y.

Curr Opin Urol. 2013 May;23(3):214-9. doi: 10.1097/MOU.0b013e32835e9f07.

PMID:
23385975
4.

Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines.

Marques RB, Dits NF, Erkens-Schulze S, van Ijcken WF, van Weerden WM, Jenster G.

PLoS One. 2011;6(8):e23144. doi: 10.1371/journal.pone.0023144. Epub 2011 Aug 4.

5.

Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer.

Rove KO, Crawford ED.

Curr Opin Urol. 2013 May;23(3):208-13. doi: 10.1097/MOU.0b013e32835fa889. Review.

PMID:
23492838
6.

Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.

Vis AN, Schröder FH.

BJU Int. 2009 Aug;104(4):438-48. doi: 10.1111/j.1464-410X.2009.08695.x. Epub 2009 Jun 24. Review.

7.

Targeted androgen pathway suppression in localized prostate cancer: a pilot study.

Mostaghel EA, Nelson PS, Lange P, Lin DW, Taplin ME, Balk S, Ellis W, Kantoff P, Marck B, Tamae D, Matsumoto AM, True LD, Vessella R, Penning T, Hunter Merrill R, Gulati R, Montgomery B.

J Clin Oncol. 2014 Jan 20;32(3):229-37. doi: 10.1200/JCO.2012.48.6431. Epub 2013 Dec 9.

8.

New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.

Sharifi N.

Expert Opin Investig Drugs. 2010 Jul;19(7):837-46. doi: 10.1517/13543784.2010.494178. Review.

PMID:
20524793
9.

The androgen/androgen receptor axis in prostate cancer.

Bluemn EG, Nelson PS.

Curr Opin Oncol. 2012 May;24(3):251-7. doi: 10.1097/CCO.0b013e32835105b3. Review.

10.

Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.

Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB.

Eur Urol. 2015 Mar;67(3):470-9. doi: 10.1016/j.eururo.2014.09.049. Epub 2014 Oct 8. Review.

PMID:
25306226
11.

Androgen action in the prostate gland.

Yadav N, Heemers HV.

Minerva Urol Nefrol. 2012 Mar;64(1):35-49. Review.

PMID:
22402316
12.

Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.

Long BJ, Grigoryev DN, Nnane IP, Liu Y, Ling YZ, Brodie AM.

Cancer Res. 2000 Dec 1;60(23):6630-40.

14.

A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.

Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SP.

BJU Int. 2008 May;101(9):1084-9. doi: 10.1111/j.1464-410X.2008.07509.x.

15.

Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.

Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M.

Cancer Res. 2004 Oct 1;64(19):7156-68.

16.

Enzalutamide for the treatment of castration-resistant prostate cancer.

Ha YS, Goodin S, DiPaola RS, Kim IY.

Drugs Today (Barc). 2013 Jan;49(1):7-13. doi: 10.1358/dot.2013.49.1.1910724. Review.

PMID:
23362491
17.

Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer.

Singh P, Hallur G, Anchoori RK, Bakare O, Kageyama Y, Khan SR, Isaacs JT.

Prostate. 2008 Oct 1;68(14):1570-81. doi: 10.1002/pros.20821.

18.

Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer.

Culig Z, Santer FR.

Steroids. 2013 Sep;78(9):851-9. doi: 10.1016/j.steroids.2013.04.012. Epub 2013 Apr 30.

PMID:
23643785
19.

Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.

Crona DJ, Milowsky MI, Whang YE.

Clin Pharmacol Ther. 2015 Dec;98(6):582-9. doi: 10.1002/cpt.256. Epub 2015 Oct 1. Review.

PMID:
26331358
20.

Androgen receptor and antiandrogen therapy in male breast cancer.

Di Lauro L, Barba M, Pizzuti L, Vici P, Sergi D, Di Benedetto A, Mottolese M, Speirs V, Santini D, De Maria R, Maugeri-SaccĂ  M.

Cancer Lett. 2015 Nov 1;368(1):20-5. doi: 10.1016/j.canlet.2015.07.040. Epub 2015 Aug 11. Review.

PMID:
26276719
Items per page

Supplemental Content

Write to the Help Desk